Focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) are 26 leading causes of primary nephrotic syndrome, yet their etiologies are unknown.
27
Evidence supports the concept that a circulating "permeability factor" or toxin acts 28 directly on the podocyte to mediate podocyte dysregulation, effacement and proteinuria.
29
In FSGS, irreversible podocyte injury causes podocyte depletion and progressive 30 glomerulosclerosis (4). Despite decades of research, both the identity and source of the 31 permeability factor(s) remain elusive (7). Whereas MCD is highly responsive to 32 glucocorticoid therapy, FSGS responds in only 40% of cases and is often resistant to 33 alternate immunosuppressive agents. This contrasts with secondary forms of FSGS, for 34 which it is often possible to treat the cause, such as HIV infection, pamidronate toxicity,
35
or morbid obesity (4). Given the dismal prognosis of primary FSGS and its potential to 36 recur in the allograft, there is pressing need for biomarkers that inform more targeted 37 therapy.
38
Against this backdrop, the recent report of B7-1 as biomarker and potential therapeutic population, which is another point of contention (1, 6) .
124
Lesson learned is that biomarker discovery requires independent validation in other 
